🔎 Trials Near Me

Pradžia › Difuzinė didelė B ląstelių limfoma › Arizona

Difuzinė didelė B ląstelių limfoma klinikiniai tyrimai Arizona

13 tyrimai dėl Difuzinė didelė B ląstelių limfoma ieško dalyvių vietose Arizona.

Miestai Arizona

Oficialus tyrimo tekstas (anglų kalba)

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Banner MD Anderson Cancer Center, Gilbert
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06500273

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic in Arizona, Scottsdale
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06834373

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Honor Health Research Institute, Scottsdale
  • University of Arizona Cancer Center, Tucson
Renkami dalyviai1/2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT05006716

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • Banner MD Anderson Cancer Center ( Site 0165), Gilbert
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167), Phoenix
  • The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06717347

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175), Glendale
Renkami dalyviai2/3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT05139017

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Ironwood Cancer & Research Centers ( Site 0204), Chandler
  • Palo Verde Cancer Specialists ( Site 0105), Glendale
  • City of Hope - Phoenix ( Site 0202), Goodyear
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT06890884

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Scottsdale, Scottsdale
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07226843

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Banner MD Anderson Cancer Center, Gilbert
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-05 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Banner MD Anderson Cancer Center, Gilbert
  • Honor Health, Scottsdale
  • Mayo Clinic Arizona, Scottsdale
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Banner MD Anderson Cancer Center, Gilbert
  • Mayo Clinic, Phoenix
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-13 · NCT04792489

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-02 · NCT05633615

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-10-20 · NCT05890352

Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.